Cytori Therapeutics Inc. (CYTX) Appoints New Executive Vice President of Marketing and Sales
Cytori Therapeutics, Inc., a developer, manufacturer, and retailer of medical technologies to allow practice of regenerative medicine, has announced the appointment of Clyde W. Shores as the new Executive Vice President of Marketing and Sales. Clyde W. Shores will be leading the Company’s various marketing initiatives for all of its product lines worldwide.
More specifically, Mr. Shores will lead Cytori’s preparations for the next generation Celution® One System for its hospital based sales. Mr. Shores will also supervise strategy and initiatives to drive the use and adoption of Cytori’s existing products, which includes the Celution® 800 and PureGraft™ Systems, along with StemSource® cell and tissue banking. Mr. Shores will also lay the foundation for newer regional and indication-based claims for the pre-existing products in Europe and the US.
“Cytori has undergone an extensive search for the ideal leader of its marketing team,” said Marc H. Hedrick, President of Cytori Therapeutics. “With his background in cell therapy, medical devices and pharmaceuticals, Clyde is uniquely qualified to drive our marketing efforts as we continue to lead the way in regenerative medicine. His entrepreneurial spirit, combined with broad experience with high growth products and industries, will allow him to integrate seamlessly with the existing culture at Cytori and add tremendous value to our marketing and sales teams.”
Mr. Shores holds 27 years of expertise in medical marketing and retail and has been involved in the launch and marketing of many cutting-edge medical products such as Amgen’s Neupogen®. Recently, Mr. Shores provided his services as the Vice President of Global Marketing for Baxter International’s Renal Business. Preceding Baxter, Mr. Shores worked with Abbott Laboratories, Prometheus Laboratories, decode Genetics, and Amgen.
During his 9 years with Amgen and tenure with various other companies, Mr. Shores established a fundamental understanding of the potential for stem cell devices and pharmaceuticals, the commercialization of state-of-the-art therapeutics and the marketing and retail capabilities necessary for the achievement of significant revenue growths in the global market.
Cytori Therapeutics, Inc. engages in the development, manufacture, and sale of medical technologies to allow the practice of regenerative medicine. Regenerative medicines focus on repairing or restoring lost or damaged tissue and cell function. The company develops its product pipeline for the treatments of cardiovascular disease, spinal disc degeneration, gastrointestinal disorders, liver and renal disease, and pelvic health conditions.
For more information on the company and its products, visit their company website: cytoritx.com
Please see disclaimer on QualityStocks website: disclaimer.qualitystocks.net
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.